Virtual Pitch Day
An exclusive live webinar for family offices
and ultra high net worth investors featuring
A Psychedelic Life Science
Thursday, September 3rd from 2-3pm EST
Cybin Corp. is a leading psychedelic life sciences company that is developing novel technologies that improve the bioavailabiliy of existing compounds to achieve the desired effects of psychedelics at lower doses and to target psychiatric and neurological conditions using psychedelics.
IP strategy covers chemically synthesized molecules, delivery mechanisms, screeners, protocols and new drug formulations.
Cybin has numerous ongoing clinical trials evaluating psychedelic compounds for the treatment of mental illnesses and addiction, including:
Phase 1a & Phase 2b clinical trials expected to be conducted in patients with Major Depressive Disorder (MDD).
Phase 2 randomized clinical trial to be conducted in patients with a smoking addiction.
Clinical study covering microdosing, or taking one-tenth of the "trip" dose, to avoid hallucinations but deliver cognitive flexibility.
Cybin CEO Doug Drysdale has over 30 years of experience in the healthcare sector and raised over $4 billion in capital and led over $5 billion in mergers and acquisition activity.
Former Head of M&A at Actavis Group, leading 15 corporate acquisitions across three continents, between 2004 and 2008, including a high-profile public hostile takeover attempt in Central Eastern Europe. Over this period, Doug raised approximately $3 billion of capital and managed lending syndicates including 25+ banks, to fund the company’s growth. Actavis was sold to Watson Pharmaceuticals in 2012 for EUR4.25 billion.
Former Director and CEO of Tedor Pharma, a family-owned contract manufacturing business. Doug’s efforts to turnaround the business resulted in 60% revenue growth in 2019, leading to Tedor being recognized as one of America’s fastest-growing companies, making it to the 2020 Inc 5000 list.
Led the turnaround of Norwich Pharmaceuticals alongside investors and became the Founding CEO of parent company, Alvogen Group. During his 5.5-year tenure as CEO, Alvogen grew from inception to $450 million in revenues across 35 countries.